|
1.
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Khasraw M and Lassman AB: Advances in the
treatment of malignant gliomas. Curr Oncol Rep. 12:26–33. 2010.
View Article : Google Scholar
|
|
3.
|
Yu Y, Ramena G and Elble RC: The role of
cancer stem cells in relapse of solid tumors. Front Biosci (Elite
Ed). 4:1528–1541. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Binda E, Visioli A, Reynolds B and Vescovi
AL: Heterogeneity of cancer-initiating cells within glioblastoma.
Front Biosci (Schol Ed). 4:1235–1248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Malik B and Nie D: Cancer stem cells and
resistance to chemo and radio therapy. Front Biosci (Elite Ed).
4:2142–2149. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Beier D, Schulz JB and Beier CP:
Chemoresistance of glioblastoma cancer stem cells - much more
complex than expected. Mol Cancer. 10:1282011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hermisson M, Klumpp A, Wick W, et al:
O6-methylguanine DNA methyltransferase and p53 status
predict temozolomide sensitivity in human malignant glioma cells. J
Neurochem. 96:766–776. 2006.
|
|
9.
|
Hegi ME, Liu L, Herman JG, et al:
Correlation of O6-methylguanine methyltransferase (MGMT)
promoter methylation with clinical outcomes in glioblastoma and
clinical strategies to modulate MGMT activity. J Clin Oncol.
26:4189–4199. 2008.
|
|
10.
|
Blough MD, Westgate MR, Beauchamp D, et
al: Sensitivity to temozolomide in brain tumor initiating cells.
Neurooncology. 12:756–760. 2010.PubMed/NCBI
|
|
11.
|
Spiegl-Kreinecker S, Pirker C, Filipits M,
et al: O6-methylguanine DNA methyltransferase protein
expression in tumor cells predicts outcome of temozolomide therapy
in glioblastoma patients. Neurooncology. 12:28–36. 2010.
|
|
12.
|
Kato T, Natsume A, Toda H, et al:
Efficient delivery of liposome-mediated MGMT-siRNA reinforces the
cytotoxity of temozolomide in GBM-initiating cells. Gene Ther.
17:1363–1371. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Ikushima H, Todo T, Ino Y, Takahashi M,
Miyazawa K and Miyazono K: Autocrine TGF-beta signaling maintains
tumorigenicity of glioma-initiating cells through Sry-related
HMG-box factors. Cell Stem Cell. 5:504–514. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Matsuda K, Sato A, Okada M, et al:
Targeting JNK for therapeutic depletion of stem-like glioblastoma
cells. Sci Rep. 2:5162012. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Sato A, Sunayama J, Okada M, et al:
Glioma-initiating cell elimination by metformin activation of FOXO3
via AMPK. Stem Cells Transl Med. 1:811–824. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Hart MG, Garside R, Rogers G, Stein K and
Grant R: Temozolomide for high grade glioma. Cochrane Database Syst
Rev. 4:CD0074152013.
|
|
17.
|
Hegi ME, Diserens AC, Godard S, et al:
Clinical trial substantiates the predictive value of
O-6-methylguanine-DNA methyltransferase promoter methylation in
glioblastoma patients treated with temozolomide. Clin Cancer Res.
10:1871–1874. 2004. View Article : Google Scholar
|
|
18.
|
Sato A, Sunayama J, Matsuda K, et al:
MEK-ERK signaling dictates DNA-repair gene MGMT expression and
temozolomide resistance of stem-like glioblastoma cells via the
MDM2-p53 axis. Stem Cells. 29:1942–1951. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Ciceroni C, Bonelli M, Mastrantoni E, et
al: Type-3 metabotropic glutamate receptors regulate
chemoresistance in glioma stem cells, and their levels are
inversely related to survival in patients with malignant gliomas.
Cell Death Differ. 20:396–407. 2013. View Article : Google Scholar
|
|
20.
|
Persano L, Pistollato F, Rampazzo E, et
al: BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by
affecting HIF-1alpha stability and MGMT expression. Cell Death Dis.
3:e4122012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Siebzehnrubl FA, Silver DJ, Tugertimur B,
et al: The ZEB1 pathway links glioblastoma initiation, invasion and
chemoresistance. EMBO Mol Med. 5:1196–1212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Ohba S, Hirose Y, Kawase T and Sano H:
Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced
cytotoxicity in human glioma cells. J Neurooncol. 95:307–316. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kanzawa T, Germano IM, Kondo Y, Ito H, Kyo
S and Kondo S: Inhibition of telomerase activity in malignant
glioma cells correlates with their sensitivity to temozolomide. Br
J Cancer. 89:922–929. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Aghi M, Rabkin S and Martuza RL: Effect of
chemotherapy-induced DNA repair on oncolytic herpes simplex viral
replication. J Natl Cancer Inst. 98:38–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Nadkarni A, Shrivastav M, Mladek AC, et
al: ATM inhibitor KU-55933 increases the TMZ responsiveness of only
inherently TMZ sensitive GBM cells. J Neurooncol. 110:349–357.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Miyazawa K: A negative regulator or just
an unconcerned passerby: phosphoinositide 3-kinase signalling in
IL-12 production. J Biochem. 152:497–499. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Jemaa M, Vitale I, Kepp O, et al:
Selective killing of p53-deficient cancer cells by SP600125. EMBO
Mol Med. 4:500–514. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Schmidt M, Budirahardja Y, Klompmaker R
and Medema RH: Ablation of the spindle assembly checkpoint by a
compound targeting Mps1. EMBO Rep. 6:866–872. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Kohsaka S, Wang L, Yachi K, et al: STAT3
inhibition overcomes temozolomide resistance in glioblastoma by
downregulating MGMT expression. Mol Cancer Ther. 11:1289–1299.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Bocangel D, Sengupta S, Mitra S and Bhakat
KK: p53-mediated down-regulation of the human DNA repair gene
O6-methylguanine-DNA methyltransferase (MGMT) via
interaction with Sp1 transcription factor. Anticancer Res.
29:3741–3750. 2009.PubMed/NCBI
|
|
31.
|
Boldogh I, Ramana CV, Chen Z, et al:
Regulation of expression of the DNA repair gene
O6-methylguanine-DNA methyltransferase via protein
kinase C-mediated signaling. Cancer Res. 58:3950–3956.
1998.PubMed/NCBI
|
|
32.
|
Pyko IV, Nakada M, Sabit H, et al:
Glycogen synthase kinase 3beta inhibition sensitizes human
glioblastoma cells to temozolomide by affecting
O6-methylguanine DNA methyltransferase promoter
methylation via c-Myc signaling. Carcinogenesis. 34:2206–2217.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Lavon I, Fuchs D, Zrihan D, et al: Novel
mechanism whereby nuclear factor kappaB mediates DNA damage repair
through regulation of O(6)-methylguanine-DNA-methyltransferase.
Cancer Res. 67:8952–8959. 2007. View Article : Google Scholar
|
|
34.
|
Chuang JY, Wang YT, Yeh SH, Liu YW, Chang
WC and Hung JJ: Phosphorylation by c-Jun NH2-terminal kinase 1
regulates the stability of transcription factor Sp1 during mitosis.
Mol Biol Cell. 19:1139–1151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Wang SA, Chuang JY, Yeh SH, et al: Heat
shock protein 90 is important for Sp1 stability during mitosis. J
Mol Biol. 387:1106–1119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Noguchi K, Kitanaka C, Yamana H, Kokubu A,
Mochizuki T and Kuchino Y: Regulation of c-Myc through
phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J
Biol Chem. 274:32580–32587. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Kitanaka C, Sato A and Okada M: JNK
signaling in the control of the tumor-initiating capacity
associated with cancer stem cells. Genes Cancer. Jan 22–2013.(Epub
ahead of print). View Article : Google Scholar
|
|
38.
|
Yoon CH, Kim MJ, Kim RK, et al: c-Jun
N-terminal kinase has a pivotal role in the maintenance of
self-renewal and tumorigenicity in glioma stem-like cells.
Oncogene. 31:4655–4666. 2012. View Article : Google Scholar : PubMed/NCBI
|
